细胞英文名:Prostate cancer cells, RM-1 cells 细胞生长:贴壁生长 细胞形态:上皮细胞样 细胞数量:1× 106个 细胞传代:1:4~1:6传代;每周换液2~3次 细胞,RM-1细胞5×106cells/瓶×2Molt-4 (human acute lymphoblastic leukemia cell)Molt-4(人急性淋巴母细胞细胞) ...
Mouse prostate cancer cell RM-1 英文别名: 中文名: 小鼠前列腺癌细胞RM-1 中文别名: 小鼠前列腺癌细胞RM-1 CBNumber: CB25533594 分子式: 分子量: 0 MOL File: Mol file 化学性质安全信息用途供应商8 小鼠前列腺癌细胞RM-1化学性质 安全信息 小鼠前列腺癌细胞RM-1性质、用途与生产工艺 ...
Here we demonstrate that a whole cell tumor vaccine can induce protective T cell immunity to a low MHC Class I-expressing mouse prostate cancer cell line, RM-1. ALVAC recombinant canarypox viruses encoding interleukin-2, interleukin-12 and tumor necrosis factor-伪 were used to create therapeutic...
英文名:RM1 mouse prostate cancer cell membrane nano micelles 品牌:舜纳纳米 SunLipo NanoTech 规格:2mL;5mL;10mL 产品说明:平均粒径150nm;视不同种生物膜包覆使载体具备长循环及靶向功能 产地:上海 包装容器:西林瓶/塑封瓶 无菌处理:是 保存条件:4度密封避光 ...
Mouse prostate cancer cell RM-1 Basic information Product Name:Mouse prostate cancer cell RM-1 Synonyms: CAS: MF: MW:0 EINECS: Product Categories: Mol File:Mol File Mouse prostate cancer cell RM-1 Chemical Properties Safety Information
Autophagy is a double-edged sword that affects tumor progression by promoting cell survival or death depending on different living contexts. The concrete mechanism by which autophagy modulates the efficacy of radiotherapy for prostate cancer (PC) remains unclear. We exposed RM-1 PC cells to X-ray...
传代方法: 1:2至1:6,每周2次。 冻存条件: 90% 完全培养基+10% DMSO,液氮储存 支原体检测: 阴性 参考文献: Baley P.A., Yoshida K., Qian W., Sehgal I., Thompson T.C. Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. J. Steroid Biochem. Mol. Bi...
In conclusion, prostate cancer-derived exosomes could reinforce CXCR4 expression in MDSCs through the TLR2/NF-κB signalling pathway, eventually promoting migration of MDSCs into tumor microenvironment in a CXCR4-CXCL12 axis-dependent manner. 1. Introduction As one of the most prevalent cancers ...
241477 Introduction: Prostate cancer is one of the most frequent malignancies affecting men, with a poor prognosis after progression to metastatic castration-resistant prostate cancer (mCRPC). Statistically, mCRPC develops in 20–30% of prostate cancer cases [1]. Cytotoxic chemotherapy, immunotherapy, ...
(McCormack RT等人,″Molecular forms of prostate-specific antigen and thehuman kallikrein gene familya new era″,Urology 45(5)729-44,1995;Karazanashvili G,Abrahamsson PA,″Prostate specific antigen and humanglandular kallikrein 2 in early detection of prostate cancer″,J.Urology 169(2)445-457,...